Our pipeline is focused on the development of targeting microRNA-based oligonucleotide therapeutics (ONTs) to treat:
- Human obesity, type 2 diabetes mellitus, dyslipidemia and MAFLD/NASH; pathologies characterized by fat accumulation, lipotoxicity, insulin resistance and chronic inflammation
- Ovarian Cancer, the most lethal form of gynecological tumors
